About Regenxbio Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://regenxbio.com/
Frequently Asked Questions
What is the 52-week range for RGNX?
The 52-week high is $16.19 and the 52-week low is $5.455.
What is the P/E ratio for RGNX?
The P/E ratio data is currently unavailable.
What is the dividend yield for RGNX?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -220.07%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -112.58%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 7.10.
Analyst Recommendation Trends
Wall Street analyst consensus for RGNX over the last few months:
Latest RGNX News
uniQure: Another Selloff On 48-Month Huntington Data; I Am (Marginally) Bullish
uniQure's BLA for AMT-130 is anchored on robust 36-month data, with the FDA signaling willingness to review. Click to read more about the Buy rating for QURE.
Regenxbio stock gains on positive gene therapy trial data
Investing.com -- Regenxbio Inc (NASDAQ:RGNX) shares rose 4.8% in premarket trading Friday after the company presented positive three-year durability data for surabgene lomparvovec in diabetic retinopathy at the Retina Society Annual Scientific Meeting.
Reported Earlier, REGENXBIO Presents Three-Year Sura-Vec Data Showing Majority Of NPDR Participants Achieved Greater Than 2-Step DRSS Improvement, No Vision-Threatening Events
Majority of Dose Level 3 participants with NPDR demonstrated a > 2-step DRSS improvement at 3 years post-one-time, in-office sura-vec gene therapy treatment, with no vision-threatening events and no additional
REGENXBIO Presents Positive Three-Year Durability Data for Surabgene Lomparvovec in Diabetic Retinopathy at Retina Society Annual Scientific Meeting
REGENXBIO Inc. (Nasdaq: RGNX) today announced positive long-term follow-up data from the Phase II ALTITUDE® study of investigational surabgenelomparvovec (sura-vec, ABBV-RGX-314) in diabetic retinopathy (DR) using suprachoroidal delivery. These new data were presented at the Retina Society 59th Annual Scientific Meeting in Los Angeles.
REGENXBIO Says All Ongoing Patent Litigation Regarding Patents-In-Suit To Be Terminated With Prejudice; Agrees Not To Sue Sarepta Or Affiliates Over Existing Elevidys Or AAVrh74-Based Capsids
On September 23, 2026, REGENXBIO Inc. (the "Company") and The Trustees of the University of Pennsylvania ("UPenn") entered into a Settlement Agreement (the "Settlement Agreement") with Sarepta
REGENXBIO Announces $39M Settlement With Sarepta Resolving All Elevidys Patent Litigation
https://www.sec.gov/ix?doc=/Archives/edgar/data/0001590877/000119312526399377/rgnx-20260923.htm
REGENXBIO Inc. (RGNX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
REGENXBIO Inc. (RGNX) Morgan Stanley 24th Annual Global Healthcare Conference September 16, 2026 8:30 AM EDTCompany ParticipantsCurran Simpson - President,...
REGENXBIO to Participate in Upcoming Investor Conferences
REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following investor conferences:
Regenxbio’s Gene Therapy Faces Another FDA Setback in Hunter Syndrome
Regenxbio Inc. (NASDAQ:RGNX) suffered another setback in its effort to bring RGX-121 to patients with Hunter syndrome. The FDA placed the experimental gene therapy on clinical hold after spinal scans identified abnormalities in five treated participants, and Reuters reported that Regenxbio shares fell more than 24% in premarket trading following the announcement. The findings add […]
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-01 | Malzahn Craig | -234 | $9.32 | $2,181 |
| 2026-09-01 | Chan Mitchell | -4,902 | $9.32 | $45,687 |
| 2026-08-27 | Ciongoli Gregory Austin | +53,407 | $9.356 | $499,676 |
| 2026-08-26 | Ciongoli Gregory Austin | +49,196 | $9.1411 | $449,706 |
| 2026-08-25 | Ciongoli Gregory Austin | +69,609 | - | - |
| 2026-08-25 | Ciongoli Gregory Austin | +15,432 | - | - |
| 2026-08-01 | PAKOLA STEVE | -7,468 | $9.69 | $72,365 |
| 2026-08-01 | Christmas Patrick J. | -4,699 | $9.69 | $45,533 |
| 2026-07-02 | PAKOLA STEVE | -2,161 | - | - |
| 2026-07-02 | PAKOLA STEVE | -2,161 | $13.64 | $29,476 |
| 2026-07-02 | PAKOLA STEVE | +2,161 | $7.86 | $16,985 |
| 2026-07-01 | PAKOLA STEVE | -36,725 | - | - |
| 2026-07-01 | PAKOLA STEVE | -36,725 | $12.86 | $472,284 |
| 2026-07-01 | PAKOLA STEVE | +36,725 | $7.86 | $288,659 |
| 2026-07-01 | Simpson Curran | -6,818 | $13.09 | $89,248 |
| 2026-06-30 | Simpson Curran | +1,453 | $10.18 | $14,792 |
| 2026-06-29 | PAKOLA STEVE | -19,608 | $11.04 | $216,472 |
| 2026-05-29 | Bennett Jean | +46,600 | - | - |
| 2026-05-29 | Bennett Jean | +9,807 | - | - |
| 2026-05-29 | Zachary Jennifer | +46,600 | - | - |
| 2026-05-29 | Zachary Jennifer | +9,807 | - | - |
| 2026-05-29 | Glucksmann Alexandra | +46,600 | - | - |
| 2026-05-29 | Glucksmann Alexandra | +9,807 | - | - |
| 2026-05-29 | Fox Allan M. | +46,600 | - | - |
| 2026-05-29 | Fox Allan M. | +9,807 | - | - |
| 2026-05-29 | Mills Kenneth T. | +46,600 | - | - |
| 2026-05-29 | Mills Kenneth T. | +9,807 | - | - |
| 2026-05-29 | Tasse Daniel | +46,600 | - | - |
| 2026-05-29 | Tasse Daniel | +9,807 | - | - |
| 2026-05-29 | STUMP DAVID C | +46,600 | - | - |
| 2026-05-29 | STUMP DAVID C | +9,807 | - | - |
| 2026-05-29 | KARABELAS ARGERIS N | +46,600 | - | - |
| 2026-05-29 | KARABELAS ARGERIS N | +9,807 | - | - |
| 2026-05-29 | MIGAUSKY GEORGE V | +46,600 | - | - |
| 2026-05-29 | MIGAUSKY GEORGE V | +9,807 | - | - |
| 2026-05-11 | PAKOLA STEVE | -15,309 | $11.02 | $168,705 |
| 2026-03-10 | PAKOLA STEVE | -5,124 | $10.35 | $53,033 |
| 2026-02-01 | PAKOLA STEVE | -5,267 | $11.16 | $58,780 |
| 2026-02-01 | Christmas Patrick J. | -4,700 | $11.16 | $52,452 |
| 2026-01-27 | Mills Kenneth T. | -225,000 | - | - |
| 2026-01-27 | Mills Kenneth T. | -221,753 | $13.41 | $2,973,708 |
| 2026-01-27 | Mills Kenneth T. | +225,000 | $13.09 | $2,945,250 |
| 2026-01-06 | Malzahn Craig | +35,402 | - | - |
| 2026-01-06 | Malzahn Craig | +65,847 | - | - |
| 2026-01-06 | Chan Mitchell | +39,650 | - | - |
| 2026-01-06 | Chan Mitchell | +73,749 | - | - |
| 2026-01-06 | PAKOLA STEVE | +35,402 | - | - |
| 2026-01-06 | PAKOLA STEVE | +65,847 | - | - |
| 2026-01-06 | Christmas Patrick J. | +39,650 | - | - |
| 2026-01-06 | Christmas Patrick J. | +73,749 | - | - |
| 2026-01-06 | Simpson Curran | +233,651 | - | - |
| 2026-01-06 | Simpson Curran | +144,864 | - | - |
| 2026-01-02 | Malzahn Craig | -1,238 | $14.4 | $17,827 |
| 2026-01-02 | PAKOLA STEVE | -18,247 | $14.4 | $262,757 |
| 2026-01-02 | Christmas Patrick J. | -9,793 | $14.4 | $141,019 |
| 2026-01-02 | Simpson Curran | -18,559 | $14.4 | $267,250 |
| 2025-12-31 | Simpson Curran | +951 | $6.9955 | $6,653 |
| 2025-10-09 | Simpson Curran | -20,811 | $12.62 | $262,635 |